强化的ChlVPP/ABVVP化疗方案及聚乙二醇化重组人粒细胞刺激因子支持用于晚期霍奇金淋巴瘤
Intensified ChlVPP/ABVVP chemotherapy regimen and pegfilgrastim support in advanced Hodgkin lymphoma.
作者信息
Cocorocchio E, Vanazzi A, Bassi S, Peccatori F, Antoniotti P, Gigli F, Travaini L, Piperno G, Pruneri G, Preda L, Biffi R, Botteri E, Negri M, Martinelli G
机构信息
Haematoncology Division.
出版信息
Ecancermedicalscience. 2010;4:184. doi: 10.3332/ecancer.2010.184. Epub 2010 Sep 8.
We present feasibility, toxicity and efficacy results of an intensified six-cycle ChlVPP/ABVVP regimen in advanced Hodgkin lymphoma (HL). From February 2004 to August 2007, 82 consecutive eligible patients were enrolled. According to the Hasenclever index, 64 patients (78%) were considered at low risk, 15 (18%) at intermediate and 3 (4%) at high risk. The most relevant toxicity was haematological: grade 3-4 neutropenia occurred in 32% of patients, grade 3-4 anaemia in 26% of patients. Severe infections and febrile neutropenia were observed in 8% of patients. With a median follow-up of 35 months (range 12-55), the three-year freedom from treatment failure (FFTF) and overall survival (OS) were 75% (95% CI 65%-86%) and 94% (95% CI 87%-99%), respectively. The intensified ChlVPP/ABVVP regimen in advanced HL is effective, does not seem to differ from standard regimens in terms of FFTF and OS and showed a favourable toxicity profile.
我们展示了强化六周期ChlVPP/ABVVP方案治疗晚期霍奇金淋巴瘤（HL）的可行性、毒性和疗效结果。从2004年2月至2007年8月，连续纳入了82例符合条件的患者。根据Hasenclever指数，64例患者（78%）被认为是低风险，15例（18%）为中度风险，3例（4%）为高风险。最相关的毒性是血液学方面的：3-4级中性粒细胞减少症发生在32%的患者中，3-4级贫血发生在26%的患者中。8%的患者出现严重感染和发热性中性粒细胞减少症。中位随访35个月（范围12-55个月），三年无治疗失败生存率（FFTF）和总生存率（OS）分别为75%（95%CI 65%-86%）和94%（95%CI 87%-99%）。强化ChlVPP/ABVVP方案治疗晚期HL有效，在FFTF和OS方面似乎与标准方案无差异，且显示出良好的毒性特征。
Zotero 插件